Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CAD | P27708 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986346 | 1.00 | L3MBTL1 (0.44) | L3MBTL1KMT2APOLBALDH1A1HSD17B10 | |
| SCHEMBL21271462 | 0.81 | L3MBTL1 (0.65) | L3MBTL1KMT2APOLBALDH1A1HSD17B10 | |
| SCHEMBL21271459 | 0.81 | L3MBTL1 (0.65) | L3MBTL1KMT2APOLBALDH1A1HSD17B10 | |
| SCHEMBL21271460 | 0.81 | L3MBTL1 (0.65) | L3MBTL1KMT2APOLBALDH1A1HSD17B10 | |
| SCHEMBL11186485 | 0.79 | GAA (0.48) | L3MBTL1KMT2APOLBALDH1A1GAA | |
| SCHEMBL5330001 | 0.79 | L3MBTL1 (0.53) | L3MBTL1KMT2APOLBALDH1A1HSD17B10 | |
| SCHEMBL5409583 | 0.74 | L3MBTL1 (0.51) | L3MBTL1KMT2APOLBALDH1A1HSD17B10 | |
| 1,6-Hexanediol SCHEMBL28962667 | 0.73 | KMT2A (0.43) | L3MBTL1KMT2APOLBALDH1A1HSD17B10 | |
| SCHEMBL7314127 | 0.71 | GAA (0.52) | L3MBTL1KMT2APOLBALDH1A1HSD17B10 | |
| SCHEMBL13559155 | 0.71 | ALDH1A1 (0.54) | L3MBTL1KMT2APOLBALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651237-A4 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | JOHNSON & JOHNSON CONSUMER (US) | 2008-10-01 | — | — | EP | claimed |
| EP-1651237-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | Galileo Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005016270-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | GALILEO PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050032751-A1 | Methods for treatment of dermatological conditions | JOHNSON & JOHNSON CONSUMER INC. | 2005-02-10 | — | — | US | claimed |
| EP-1651237-B1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | JOHNSON & JOHNSON CONSUMER (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20100202989-A1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | WANG BING | 2010-08-12 | — | — | US | disclosed |
| US-7737179-B2 | Methods for treatment of dermatological conditions | J&J CONSUMER COMPANIES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1651237-A4 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | JOHNSON & JOHNSON CONSUMER (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1651237-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | Galileo Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005016270-A2 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | GALILEO PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050032751-A1 | Methods for treatment of dermatological conditions | JOHNSON & JOHNSON CONSUMER INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202989-A1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | KRT18, CUTA, TUBB1 | L3MBTL1 4560/4885KMT2A 3319/4885POLB 1164/4885 |
| US-20050032751-A1 | Methods for treatment of dermatological conditions | KRT18, CUTA, TUBB1 | L3MBTL1 4560/4885KMT2A 3319/4885POLB 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.